The Medipattern Corporation

The Medipattern Corporation

April 22, 2008 06:30 ET

Medipattern's B-CAD™ Approved for Sale in China


TORONTO, ONTARIO--(Marketwire - April 22, 2008) -

Attention: Business/Financial Editors

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better informed biopsy decisions and to permit a higher standard of care for the millions of patients at risk of cancer, is pleased to announce receipt of State Food and Drug Administration (SFDA) approval in the People's Republic of China for its B-CAD™ product. Beijing Eastwide, Medipattern's reseller in China, was instrumental in submitting B-CAD for SFDA approval and will promote and market B-CAD throughout mainland China.

"Breast cancer is the fastest growing threat for the women of China. B-CAD is effective, easy to use, and easy to understand. Beijing Eastwide saw B-CAD's potential more than a year ago, facilitating introductions and technology evaluations," comments Madam Zhao, President of Beijing Eastwide. "We placed our initial order for the units which will be used for breast screening as well as diagnostic breast ultrasound to fight cancer in China."

B-CAD is installed and now in daily use at the newly created Breast Imaging Center at the People's Liberation Army (PLA) 301 Hospital, China's premier hospital and research center located in Beijing. Medical practitioners and technicians will come to Beijing to be trained and certified on the use of B-CAD through a Continuing Medical Education initiative developed by the PLA 301.

"B-CAD improves patient care in detecting malignant cancer at an earlier stage and for those with benign lesions B-CAD reduces patient stress by correctly identifying benign morphology earlier on in the diagnostic process," comments Dr. Tang, Director of Ultrasound and the newly created Breast Center at the PLA 301. "B-CAD offers standardization which helps to ensure the quality of care that we can offer to our patients."

"In a large-scale, blinded study, we showed that B-CAD increases diagnostic accuracy by 44 percent on malignant lesions less than 1 cm in size and increases accuracy in correctly identifying benign lesions by 20 percent. B-CAD effectively helps the physician identify both benign and malignant lesions," comments Dr. Li, Director of Ultrasound Breast Imaging at the PLA 301.

"We congratulate Madam Zhao and her entire staff at Beijing Eastwide for diligently supporting the many questions during the SFDA process and facilitating the introduction of B-CAD to China," comments Jeff Collins, CEO of The Medipattern Corporation. "We would like to express our appreciation to Dr. Tang, Dr. Li and the staff of the PLA 301 for proactively planning the incorporation of B-CAD as part of the breast imaging protocol, creating the physician training program and hosting training for all of the other doctors and facilities in an effort to standardize ultrasound breast care throughout China."

About Beijing Eastwide Medical, Ltd.

Beijing Eastwide Medical, Ltd. is headquartered in Beijing, PRC, and has an extensive sales network, with more than 20 offices in various provinces throughout China. The company has a division specializing in the sale of women's health products to breast centres and hospitals. Their products include mammography systems, ultrasound systems, and biopsy systems.

Upcoming Events:

Medipattern will participate in the following events:

- American Society of Breast Surgeons (ASBS) Annual Meeting, April 30 to May 4, New York City, NY, USA, exhibiting with partner Physicians Consultants, Inc.

- Advanced Breast Imaging Symposium, May 3 to 4, Ankara, Turkey, exhibiting with partner: Teknikel TIC. VE SAN A.S.

- American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, May 3 to 7, New Orleans, LA, USA, exhibiting with partner GE Healthcare

- 33rd National Conference on Breast Cancer, American College of Radiology (ACR) Society of Breast Imaging (SBI), May 8 to 10, Orlando, FL, USA, partnering with GE Walker of Tampa, Florida and GE Healthcare

- The Leading Edge Ultrasound Conference, May 20 to 23, Atlantic City, NJ, USA, exhibiting with partner: GE Healthcare

- Chicago International Breast Course, September 11 to 14, Chicago, IL, USA

- Radiological Society of North America (RSNA), November 30 to December 5, Chicago, IL, USA

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CADMRI™. Both have received awards for innovation in the industry. The B-CAD products, part of the Company's CADENZA™ platform, use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in medical images. Please visit the company's website at:

B-CAD™ and B-CADMRI™ are trademarks of The Medipattern Corporation.
Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information